Phytochemicals targeting diabetes and malaria: Chemical diversity, mechanistic insights, and prospects for dual-action therapeutics

Authors

  • Stanley Irobekhian Reuben Okoduwa Department of Research and Innovation Management, Nigerian Institute of Leather and Science Technology, Zaria Author
    • Conceptualization
    • Formal Analysis
    • Methodology
    • Investigation
    • Supervision
    • Validation
    • Writing – Original Draft Preparation
    • Writing – Review & Editing
    Competing Interests

    None

  • Daniel Hassan Mhya Department of Medical Biochemistry, Abubakar Tafawa Balewa University, Bauchi, Nigeria Author
    • Resources
    • Data Curation
    • Formal Analysis
    • Investigation
    • Writing – Original Draft Preparation
    Competing Interests

    None

  • Asad Abbas Department of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, 60800, Pakistan Author
    • Writing – Review & Editing
    • Validation
    • Formal Analysis
    Competing Interests

    None

  • Cyril Ohikhatemen Ahonsi Department of Product Development and Quality Assurance, Nigeria Natural Medicine Development Agency, Lagos, Nigeria Author
    • Formal Analysis
    • Data Curation
    • Validation
    Competing Interests

    None

  • Ibrahim Abdulwaliyu Scientific and Industrial Research Department, National Research Institute for Chemical Technology, Zaria, Nigeria Author
    • Data Curation
    • Formal Analysis
    • Investigation
    • Project Administration
    • Validation
    Competing Interests

    None

  • Muhammad Usman Khalid Department of Food Sciences, Faculty of Food, Nutrition and Home Sciences, GIFT University, Gujranwala, Pakistan Author
    • Formal Analysis
    • Validation
    • Visualization
    • Investigation
    Competing Interests

    None

  • Ugochi Judith Okoduwa Industrial and Environmental Pollution Department, National Research Institute for Chemical Technology, Zaria, Nigeria. Author
    • Data Curation
    • Formal Analysis
    • Methodology
    • Validation
    Competing Interests

    None

DOI:

https://doi.org/10.67867/ccj.2026v10i3.10

Keywords:

Diabetes mellitus, malaria, dual-action therapeutics

Abstract

Diabetes mellitus and malaria are major health challenges in tropical and subtropical regions, creating a need for therapeutic strategies addressing metabolic and infectious disease processes. This review aimed to systematically identify and synthesise plant-derived compounds with reported antidiabetic, antimalarial, or dual antidiabetic–antimalarial activities, with emphasis on their chemical diversity, biological activities, proposed molecular mechanisms, and levels of supporting evidence. A structured literature search was conducted for studies published from January 2015 to December 2025 using Google Scholar, PubMed, ScienceDirect, SciELO, EMBASE, Scopus and Web of Science. Relevant studies reporting antidiabetic, antimalarial or dual activities of plant-derived compounds were evaluated and synthesised according to chemical class, biological activity and proposed molecular mechanisms. Of 2,313 records identified, 272 articles met the eligibility criteria. A total of 258 phytochemicals were identified, including 135 with reported antidiabetic activity, 109 with antimalarial activity and 14 chemically defined compounds with evidence of both activities. Antidiabetic effects involved inhibition of carbohydrate-hydrolysing enzymes, modulation of insulin signalling and glucose uptake, and attenuation of oxidative stress and inflammation. Antimalarial effects included inhibition of parasite enzymes and metabolic processes, interference with haem-associated pathways, and disruption of parasite cellular functions. The dual-action compounds represented diverse classes, including alkaloids, flavonoids, phenolics, terpenoids, triterpenoids and xanthones. The review consolidates the reported chemical and biological diversity of phytochemicals with antidiabetic and antimalarial activities and identifies a focused group of compounds with evidence of dual activity. This provides a basis for prioritising multifunctional natural-product leads while highlighting the need for stronger molecular target validation and translational evidence. Phytochemicals provide a diverse reservoir of compounds with potentially relevant activities against both diseases. The 14 dual-action compounds represent a focused discovery space for multifunctional natural-product leads. However, evidence remains heterogeneous and predominantly preclinical. Future studies should prioritise molecular target validation, structure–activity relationships, pharmacokinetics, bioavailability, safety and efficacy in disease-relevant diabetes–malaria models.

Downloads

Download data is not yet available.

References

[1]. S.I.R. Okoduwa, I.A. Umar, B.D. James, and H. Inuwa, “Anti-Diabetic Potential of Ocimum gratissimum Leaf Fractions in Fortified Diet-Fed Streptozotocin Treated Rat Model of Type-2 Diabetes,” Medicines, vol. 4, no. 4, p. 73, Oct. 2017, doi: 10.3390/medicines4040073.

[2]. I. Genitsaridi et al., “11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050,” The Lancet Diabetes & Endocrinology, vol. 14, no. 2, pp. 149–156, Dec. 2025, doi: 10.1016/s2213-8587(25)00299-2.

[3]. World Health Organization. (2025). World malaria report 2025: Addressing the threat of antimalarial drug resistance. World Health Organization. https://www.who.int/publications/i/item/9789240117822

[4]. J. L. Siqueira-Neto, K. J. Wicht, K. Chibale, J. N. Burrows, D. A. Fidock, and E. A. Winzeler, “Antimalarial drug discovery: progress and approaches,” Nature Reviews Drug Discovery, vol. 22, no. 10, pp. 807–826, Aug. 2023, doi: 10.1038/s41573-023-00772-9.

[5]. S. I. R. Okoduwa, I. Abdulwaliyu, B.E. Igiri, S.O. Arekemase, U.J. Okoduwa, J.F. Itiat, M.N. Egbule, and R.A Mustapha, “Multi-therapeutic potential of flavonoids as an essential component in nutraceuticals for the treatment and management of human diseases,” Phytomedicine Plus, vol. 4, no. 2, p. 100558, Mar. 2024, doi: 10.1016/j.phyplu.2024.100558.

[6]. I. Abdulwaliyu, S. O. Arekemase, J. A. Adudu, M. L. Batari, M. N. Egbule, and S. I. R. Okoduwa, “Investigation of the medicinal significance of phytic acid as an indispensable anti-nutrient in diseases,” Clinical Nutrition Experimental, vol. 28, pp. 42–61, Nov. 2019, doi: 10.1016/j.yclnex.2019.10.002.

[7]. J. Cheng, Li, J., Xiong, R.-G., Wu, S.-X., Xu, X.-Y., Tang, G.-Y., Huang, S.-Y., Zhou, D.-D., Li, H.-B., Feng, Y., & Gan, R.-Y.., “Effects and mechanisms of anti-diabetic dietary natural products: an updated review,” Food & Function, vol. 15, no. 4, pp. 1758–1778, Jan. 2024, doi: 10.1039/d3fo04505f.

[8]. Y. N. Ashagrie, Chaubey, K. K., Tadesse, M. G., Dayal, D., Bachheti, R. K., Rai, N., Pramanik, A., Lakhanpal, S., Kandwal, A., and Bachheti, A, “Antidiabetic phytochemicals: an overview of medicinal plants and their bioactive compounds in diabetes mellitus treatment,” Zeitschrift Für Naturforschung C, vol. 80, no. 9–10, pp. 457–479, Jan. 2025, doi: 10.1515/znc-2024-0192.

[9]. O. Okpe, E.E. Agada, S.I.R. Okoduwa, V.A. Upev, S.M. Abu, and O. Adakole. “Aqueous stem bark extract of Mangifera indica suppresses parasitemia and ameliorates anaemia in mice model of malarial infection”. Malaysian Journal of Biochemistry and Molecular Biology, vol.3: pp. 105-112, 2021

[10]. D. Muñoz-Verbel, J. Mendoza-Galiz, E. Cueto-Almeida, E. Romero-Cueto, E. Contreras-Puentes, and N. Contreras-Puentes, “Bioactive compounds as therapeutic proposals against Plasmodium falciparum: A systematic review,” Biochemical Systematics and Ecology, vol. 115, p. 104848, May 2024, doi: 10.1016/j.bse.2024.104848.

[11]. R. M. Carrillo-Larco, C. Altez-Fernandez, and C. Ugarte-Gil, “Is diabetes associated with malaria and malaria severity? A systematic review of observational studies,” Wellcome Open Research, vol. 4, p. 136, Dec. 2019, doi: 10.12688/wellcomeopenres.15467.3.

[12]. A. G. S. Moore and S. I. R. Okoduwa, “Modulation of PDX1 gene expression and glycemic control by Citrullus lanatus in experimental type 2 diabetes,” Scientific Reports, vol. 16, no. 1, p. 3793, Jan. 2026, doi: 10.1038/s41598-025-33982-9.

[13]. J.-H. Ch’ng, Moll, K., Wyss, K., Hammar, U., Rydén, M., Kämpe, O., Färnert, A., & Wahlgren, M., “Enhanced virulence of Plasmodium falciparum in blood of diabetic patients,” PLoS ONE, vol. 16, no. 6, p. e0249666, Jun. 2021, doi: 10.1371/journal.pone.0249666.

[14]. F. McQuaid and J. A. Rowe, “Rosetting revisited: a critical look at the evidence for host erythrocyte receptors inPlasmodium falciparumrosetting,” Parasitology, vol. 147, no. 1, pp. 1–11, Aug. 2019, doi: 10.1017/s0031182019001288.

[15]. M. J. Page et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” BMJ, vol. 372, p. n71, Mar. 2021, doi: 10.1136/bmj.n71.

[16]. M. J. Page et al., “PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews,” BMJ, vol. 372, p. n160, Mar. 2021, doi: 10.1136/bmj.n160.

[17]. M. Liu, C. Liu, P. Zhaxi, X. Kou, Y. Liu, and Z. Xue, “Research Progress on Hypoglycemic Effects and Molecular Mechanisms of flavonoids: a review,” Antioxidants, vol. 14, no. 4, p. 378, Mar. 2025, doi: 10.3390/antiox14040378.

[18]. W. Yu, L. Fan, M. Wang, B. Cao, and X. Hu, “Pterostilbene improves insulin resistance caused by advanced glycation end products (AGEs) in hepatocytes and mice,” Molecular Nutrition & Food Research, vol. 65, no. 15, p. e2100321, Jun. 2021, doi: 10.1002/mnfr.202100321.

[19]. S. I. R. Okoduwa, Mhya, D.H., Abdulwaliyu, I., Igiri, B.E., Okoduwa, U.J., Arthur, D.E., Laleye, A.O., Osang, G.J., Onaleye, O.L., & Nathyns-Pepple, E., “Phytomedicine approach for management of diabetes mellitus: an overview of scientifically confirmed medicinal plants with hypoglycaemic properties and their probable mechanism of action,” Phytochemistry Reviews, vol. 24, no. 2, pp. 1691–1751, Jun. 2024, doi: 10.1007/s11101-024-09984-2

[20]. Y. Liu et al., “A comprehensive review on the phytochemistry, pharmacokinetics, and antidiabetic effect of Ginseng,” Phytomedicine, vol. 92, p. 153717, Sep. 2021, doi: 10.1016/j.phymed.2021.153717.

[21]. S. Ghafouri-Fard et al., “The effects of Ginsenosides on PI3K/AKT signaling pathway,” Molecular Biology Reports, vol. 49, no. 7, pp. 6701–6716, Feb. 2022, doi: 10.1007/s11033-022-07270-y

[22]. Z. Li et al., “Effective dose/duration of natural flavonoid quercetin for treatment of diabetic nephropathy: A systematic review and meta-analysis of rodent data,” Phytomedicine, vol. 105, p. 154348, Jul. 2022, doi: 10.1016/j.phymed.2022.154348.

[23]. D. Thabah, D. Syiem, C. L. Pakyntein, S. Banerjee, C. E. Kharshiing, and A. Bhattacharjee, “Potentilla fulgens upregulate GLUT4, AMPK, AKT and insulin in alloxan-induced diabetic mice: an in vivo and in silico study,” Archives of Physiology and Biochemistry, vol. 129, no. 5, pp. 1071–1083, Mar. 2021, doi: 10.1080/13813455.2021.1897145.

[24]. R. M. Suryawanshi et al., “ADME, Toxicity, Molecular Docking, Molecular Dynamics, Glucokinase activation, DPP‐IV, α‐amylase, and α‐glucosidase Inhibition Assays of Mangiferin and Friedelin for Antidiabetic Potential,” Chemistry & Biodiversity, vol. 22, no. 5, p. e202402738, Dec. 2024, doi: 10.1002/cbdv.202402738

[25]. N. Tajuddeen and F. R. Van Heerden, “Antiplasmodial natural products: an update,” Malaria Journal, vol. 18, no. 1, p. 404, Dec. 2019, doi: 10.1186/s12936-019-3026-1.

[26]. B. D. Bekono, B. D., Ntie-Kang, F., Onguéné, P. A., Lifongo, L. L., Sippl, W., Fester, K., and Owono, L. C. O., “The potential of anti-malarial compounds derived from African medicinal plants: a review of pharmacological evaluations from 2013 to 2019,” Malaria Journal, vol. 19, no. 1, p. 183, May 2020, doi: 10.1186/s12936-020-03231-7.

[27]. G. De Jesus Gomes Ribeiro, S. L. R. Yan, G. Palmisano, and C. Wrenger, “Plant Extracts as a Source of Natural Products with Potential Antimalarial Effects: An Update from 2018 to 2022,” Pharmaceutics, vol. 15, no. 6, p. 1638, Jun. 2023, doi: 10.3390/pharmaceutics15061638.

[28]. M. B. V. D. Santos, A. B. De Oliveira, and R. H. V. Mourão, “Brazilian plants with antimalarial activity: A review of the period from 2011 to 2022,” Journal of Ethnopharmacology, vol. 322, p. 117595, Dec. 2023, doi: 10.1016/j.jep.2023.117595.

[29]. F. Guerra and E. A. Winzeler, “New targets for antimalarial drug discovery,” Current Opinion in Microbiology, vol. 70, p. 102220, Oct. 2022, doi: 10.1016/j.mib.2022.102220.

[30]. N. A. U. M. Saufi, U. U. M. Hatta, F. N. A. A. Rashid, and M. F. Mohammat, “Alkaloids as antimalarial compounds: A review of recent studies,” Mini-Reviews in Organic Chemistry, vol. 20, no. 8, pp. 786–799, Oct. 2022, doi: 10.2174/1570193x20666221018090845

[31]. E. Abdel-ٍٍSattar, H. M. Abdallah, S. El-Mekkawy, C. Ichino, H. Kiyohara, and H. Yamada, “Antimalarial alkaloid from Hypoestes forskaolii,” Experimental Parasitology, vol. 211, p. 107851, Feb. 2020, doi: 10.1016/j.exppara.2020.107851.

[32]. K. A. De Villiers and T. J. Egan, “HEME detoxification in the malaria parasite: a target for antimalarial drug development,” Accounts of Chemical Research, vol. 54, no. 11, pp. 2649–2659, May 2021, doi: 10.1021/acs.accounts.1c00154.

[33]. N. Gogoi, D. Chetia, B. Gogoi, and A. Das, “Multiple-targets Directed Screening of Flavonoid Compounds from Citrus Species to find out Antimalarial Lead with Predicted Mode of Action: An In Silico and Whole Cell-based In vitro Approach,” Current Computer - Aided Drug Design, vol. 17, no. 1, pp. 69–82, Dec. 2019, doi: 10.2174/1573409916666191226103000.

[34]. Y. Upegui et al., “In vivo Antimalarial Activity of α‐Mangostin and the New Xanthone δ‐Mangostin,” Phytotherapy Research, vol. 29, no. 8, pp. 1195–1201, May 2015, doi: 10.1002/ptr.5362.

[35]. W. Xie et al., “Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis,” Frontiers in Pharmacology, vol. 13, p. 1015045, Nov. 2022, doi: 10.3389/fphar.2022.1015045.

[36]. A. Sun et al., “Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies,” Frontiers in Pharmacology, vol. 15, p. 1368950, Jun. 2024, doi: 10.3389/fphar.2024.1368950.

[37]. Y. Bare, D. R. T. Sari, A. D. Nita, and M. M. Taek, “Berberine: a potential inhibitor of dihydrofolate reductase- thymidylate synthase (DHFR-TS) for malaria,” Biosfer Jurnal Tadris Biologi, vol. 13, no. 1, pp. 93–99, Oct. 2022, doi: 10.24042/biosfer.v13i1.11145.

[38]. C. K. Tudu et al., “Unravelling the pharmacological properties of cryptolepine and its derivatives: a mini-review insight,” Naunyn-Schmiedeberg S Archives of Pharmacology, vol. 396, no. 2, pp. 229–238, Oct. 2022, doi: 10.1007/s00210-022-02302-7.

[39]. F. Zhong, Y. Chen, J. Chen, H. Liao, Y. Li, and Y. Ma, “Jatrorrhizine: A Review of Sources, pharmacology, pharmacokinetics and Toxicity,” Frontiers in Pharmacology, vol. 12, p. 783127, Jan. 2022, doi: 10.3389/fphar.2021.783127.

[40]. P. Okechukwu et al., “In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes,” Pharmacia, vol. 67, no. 4, pp. 363–371, Nov. 2020, doi: 10.3897/pharmacia.67.e58392.

[41]. S. Ortiz et al., “Correlation study on methoxylation pattern of flavonoids and their heme-targeted antiplasmodial activity,” Bioorganic Chemistry, vol. 104, p. 104243, Aug. 2020, doi: 10.1016/j.bioorg.2020.104243.

[42]. R. Abdulah et al., “Catechin isolated from Garcinia celebica leaves inhibit Plasmodium falciparum growth through the induction of oxidative stress,” Pharmacognosy Magazine, vol. 13, no. 50, p. 301, Jan. 2017, doi: 10.4103/pm.pm_571_16.

[43]. L. T. Marton et al., “The effects of curcumin on diabetes mellitus: a systematic review,” Frontiers in Endocrinology, vol. 12, p. 669448, May 2021, doi: 10.3389/fendo.2021.669448.

[44]. C. Dohutia, D. Chetia, K. Gogoi, and K. Sarma, “Design, in silico and in vitro evaluation of curcumin analogues against Plasmodium falciparum,” Experimental Parasitology, vol. 175, pp. 51–58, Feb. 2017, doi: 10.1016/j.exppara.2017.02.006.

[45]. A. H. Ali, S. Sudi, R. Basir, N. Embi, and H. M. Sidek, “The Antimalarial Effect of Curcumin Is Mediated by the Inhibition of Glycogen Synthase Kinase-3 β,” Journal of Medicinal Food, vol. 20, no. 2, pp. 152–161, Feb. 2017, doi: 10.1089/jmf.2016.3813.

[46]. Y. Yang et al., “Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review,” Frontiers in Endocrinology, vol. 13, p. 990299, Sep. 2022, doi: 10.3389/fendo.2022.990299.

[47]. J. H. Zothantluanga, Abd. K. Umar, K. Aswin, S. Rajkhowa, and D. Chetia, “Revelation of potential drug targets of luteolin in Plasmodium falciparum through multi-target molecular dynamics simulation studies,” Journal of Biomolecular Structure and Dynamics, vol. 42, no. 21, pp. 11612–11628, Sep. 2023, doi: 10.1080/07391102.2023.2263875.

[48]. N. T. Astuti, P. R. Novitasari, R. Tjandrawinata, A. E. Nugroho, and S. Pramono, “Anti‐diabetic effect of andrographolide from Sambiloto herbs (Andrographis paniculata (Burm.f.) Nees) through the expression of PPARγ and GLUT‐4 in adipocytes,” Indonesian Journal of Biotechnology, vol. 27, no. 4, p. 203, Dec. 2022, doi: 10.22146/ijbiotech.68800.

[49]. M. K. Dwivedi, S. Mishra, S. Sonter, and P. K. Singh, “Diterpenoids as potential anti-malarial compounds from Andrographis paniculata,” Beni-Suef University Journal of Basic and Applied Sciences, vol. 10, no. 1, Jan. 2021, doi: 10.1186/s43088-021-00098-8.

[50]. R. Yan et al., “Bioactivities and Structure‐Activity Relationships of Maslinic Acid Derivatives: A review,” Chemistry & Biodiversity, vol. 21, no. 2, p. e202301327, Dec. 2023, doi: 10.1002/cbdv.202301327.

[51]. S.-P. Chen et al., “Mangosteen xanthone γ-mangostin exerts lowering blood glucose effect with potentiating insulin sensitivity through the mediation of AMPK/PPARγ,” Biomedicine & Pharmacotherapy, vol. 144, p. 112333, Oct. 2021, doi: 10.1016/j.biopha.2021.112333

[52]. Z. Ibraheem, Z. O., Basir, R., Majid, R. A., Alapid, A. A., Sedik, H., Sabariah, M., Faruq, M. O., & Chin, V., “In vitro antiplasmodium and chloroquine resistance reversal effects of mangostin,” Pharmacognosy Magazine, vol. 16, no. 70, p. 276, Jan. 2020, doi: 10.4103/pm.pm_510_19.

[53]. Z. O. Ibraheem, R. A. Majid, S. M. Noor, M. D. Farook, and R. Basir, “Effect of mangostin on the functional activity and integrity of the Plasmodium falciparum infected and Uninfected red blood cells membrane,” Nigerian Journal of Parasitology, vol. 45, no. 1, pp. 173–186, Mar. 2024, doi: 10.4314/njpar.v45i1.19.

[54]. C. Suhandi et al., “Updating the pharmacological effects of Α-Mangostin compound and unraveling its mechanism of action: a computational study review,” Drug Design Development and Therapy, vol. Volume 18, pp. 4723–4748, Oct. 2024, doi: 10.2147/dddt.s478388.

[55]. C. Moneriz, P. Marín-García, A. García-Granados, J. M. Bautista, A. Diez, and A. Puyet, “Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages,” Malaria Journal, vol. 10, no. 1, p. 82, Apr. 2011, doi: 10.1186/1475-2875-10-82.

[56]. V. Imieje, Zaki, A. A., Fasinu, P. S., Ali, Z., Khan, I. A., Tekwani, B., Khan, S. I., Nosa, E. O., & Falodun, A., “Antiprotozoal and Cytotoxicity Studies of Fractions and Compounds from Enantia chlorantha,” Tropical Journal of Natural Product Research, vol. 1, no. 2, pp. 89–94, Aug. 2017, doi: 10.26538/tjnpr/v1i2.8.

[57]. Gaurav et al., “TLC-MS Bioautography-Based Identification of Free-Radical scavenging, Α-Amylase, and Α-Glucosidase inhibitor compounds of antidiabetic tablet BGR-34,” ACS Omega, vol. 5, no. 46, pp. 29688–29697, Nov. 2020, doi: 10.1021/acsomega.0c02995.

[58]. B. Ma, J. Tong, G. Zhou, Q. Mo, J. He, and Y. Wang, “Coptis chinensis inflorescence ameliorates hyperglycaemia in 3T3-L1 preadipocyte and streptozotocin-induced diabetic mice,” Journal of Functional Foods, vol. 21, pp. 455–462, Jan. 2016, doi: 10.1016/j.jff.2015.12.021.

[59]. C. Moneriz, J. Mestres, J. M. Bautista, A. Diez, and A. Puyet, “Multi‐targeted activity of maslinic acid as an antimalarial natural compound,” FEBS Journal, vol. 278, no. 16, pp. 2951–2961, Jun. 2011, doi: 10.1111/j.1742-4658.2011.08220.x.

[60]. Y. Wang et al., “New drug discovery and development from natural products: Advances and strategies,” Pharmacology & Therapeutics, vol. 264, p. 108752, Nov. 2024, doi: 10.1016/j.pharmthera.2024.108752.

[61]. D. K. Yadav, S. Kumar, M. K. Teli, R. Yadav, and S. Chaudhary, “Molecular Targets for Malarial Chemotherapy: A review,” Current Topics in Medicinal Chemistry, vol. 19, no. 10, pp. 861–873, Jun. 2019, doi: 10.2174/1568026619666190603080000.

[62]. P. Tang et al., “Challenges and opportunities for improving the druggability of natural product: Why need drug delivery system?,” Biomedicine & Pharmacotherapy, vol. 164, p. 114955, Jun. 2023, doi: 10.1016/j.biopha.2023.114955.

[63]. S. Gould and M. V. Templin, “Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and/or anionic charges). Data review suggests an emerging pattern,” Toxicology Letters, vol. 384, pp. 14–29, Jul. 2023, doi: 10.1016/j.toxlet.2023.07.011.

Additional Files

Published

2026-09-30

Data Availability Statement

All data are available within the manuscript

Issue

Section

Review Papers

How to Cite

Phytochemicals targeting diabetes and malaria: Chemical diversity, mechanistic insights, and prospects for dual-action therapeutics. (2026). ChemClass Journal, 10(3), 77-102. https://doi.org/10.67867/ccj.2026v10i3.10

Share

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.